DANU-PH2B-T2D — citing documents
Every Institute document that draws on this record.
§5Citing documents
This page records every Institute document that draws on DANU-PH2B-T2D. A trial abstract is a node in the document set rather than a leaf: it is cited by the monographs that use its estimate and by the syntheses that include it, and those citations are listed here so that the flow of an estimate through the document set can be followed in both directions.
§5.1Monograph evidence extracts
Table 7. Monograph evidence extracts that draw on this trial.
| Compound | Indication | Certainty there |
|---|---|---|
| Danuglipron | Type 2 diabetes mellitus | Moderate |
§5.2Evidence syntheses
Table 8. Evidence syntheses that include this trial among their contributing studies.
| Synthesis | Review type | Certainty |
|---|---|---|
| Gastrointestinal adverse events with incretin receptor agonists | Safety review | High |
| Oral compared with injectable presentations of glucagon-like peptide-1 receptor agonism | Network meta-analysis | Moderate |
| Discontinued development programmes as evidence | Methodological review | Moderate |
§5.3Other records in the same programme
This record does not belong to a programme with other records in the Institute's set.
§5.4Reference
The Institute holds no publication reference for this trial. Where a trial is real and its report has not been obtained, the record says so rather than citing a source it does not hold.